As a clinician imagine:-A 27-year-old patient presents with chronic cough reportingcigarette consumption(approximately 15 cigarettes per day)and vaping 2Juul pods perday3 to 4 days per week.At baseline the patient is found have urinary total nicotine equivalents(TNEs*) of 154.67nmoles/ml. You place the patient on Chantix and a follow-up visit in10 days demonstrates nicotine consumption has been reduced by 46% to 83.52nmoles/ml.

JUUL® is a registered mark of JUUL Labs, Inc., registered in the United States, European Union and elsewhere. TNEs are the molar sum of excreted nicotine and nicotine metabolites.

Imagine : - A heavy smoker (more than 40 cigarettes per day and 3 to 5 cigars per week) presents with COPD. At baseline urinary TNEs are measured at 210.29 nmoles/ml. You recommend a 21mg transdermal nicotine patch with supplemental 4mg nicotine mini-lozenges PRN. At 1-week follow-up the patient is found to have urinary TNEs of 53.35 nmoles/ml. He reports he is tobacco abstinent with severe tobacco withdrawal symptoms which is explained by his low percentage of nicotine replacement compared to baseline. Based on studies in peer reviewed journals and new FDA recommendations you recommend your patient use two 21mg transdermal nicotine patches each day and significantly increase 4mg nicotine mini-lozenges daily

Imagine : - A 24-year-old female patient is attempting to become pregnant. During consultation, she reports smoking “only” 3 to 5 cigarettes per week and is found to have urinary TNEs of 23.50 nmoles/ml. Using this information, you convince her to use a nicotine replacement product instead of smoking. 


CPT and HCPCS codes reimburse as much as $100 or more for each cloud-based IntelliQuit Mobile App 15-minute assay. Insurance and tobacco treatment consulting is available from IntelliQuit experts and key opinion leaders.Priority consulting is available to those who purchase NicCheck biostrips and download the IntelliQuit Mobile App.


  • Addressing the Evidence for FDAN icotine Replacement Therapy Label Changes-A Policy Statement ofthe ATTUD and the SRNT.

  • Serum nicotine and cotinine levels during nicotine-patch therapy

  • 2018 American College of Cardiology Expert Consensus Decision Pathway on Tobacco Cessation Treatment

  • A Randomized Placebo-Controlled Trial of Varenicline for Smoking Cessation Allowing Flexible Quit Dates

  • A 12-Week Double-Blind, Placebo-Controlled Study of Bupropion SR Added to High-Dose Dual Nicotine Replacement Therapy for Smoking Cessation or Reduction in Schizophrenia

  • 'Cut down to quit' with nicotine replacement therapies in smoking cessation- a systematic review of effectiveness and economic analysis

  • The Efficacy of Varenicline Compared to Placebo for Smoking Cessation Using a Reduce-to-Quit Strategy

  • Adapting Smoking Cessation Treatment According to Initial Response to Precessation Nicotine Patch

  • Are higher doses of nicotine replacement more effective for smoking cessation

  • Clinical Strategies to Enhance the Efficacy of Nicotine Replacement Therapy for Smoking Cessation- A Review of the Literature

  • Combination Therapy of Varenicline With NRT Is Better Than Varenicline Alone - a Systematic Review

  • Combination Varenicline Bupropion Treatment Benefits Highly Dependent Smokers in an Adaptive Smoking Cessation Paradigm

  • Triple Combination Pharmacotherapy for Medically Ill Smokers

  • National Academies of Science-Public Health Consequences of E-Cigarettes

  • Improvement of Smoking Abstinence Rates with Increased Varenicline Dosage